L-755,507

Pricing Availability   Qty
Cat.No. 2197 - L-755,507 | C30H40N4O6S | CAS No. 159182-43-1
Description: Very potent and selective β3 partial agonist
Chemical Name: 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-benzenesulfonamide
Purity: ≥98% (HPLC)
Datasheet
Citations (4)
Reviews
Literature

Biological Activity

Potent β3-adrenergic receptor partial agonist > 1000-fold selective over β1- and β2-adrenoceptors (EC50 values are 0.43, 580 and > 10000 nM for activation of cloned human β3-, β1- and β2-adrenoceptors respectively). Stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM). Enhances CRISPR-mediated homology-directed repair (HDR) efficiency 2-3-fold for large fragments and ~9-fold for point mutations, in human induced pluripotent stem cells (iPSCs).

Compound Libraries

L-755,507 is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 584.73
Formula C30H40N4O6S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 159182-43-1
PubChem ID 9829836
InChI Key NYYJKMXNVNFOFQ-MHZLTWQESA-N
Smiles O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 58.47 100
ethanol 58.47 100

Preparing Stock Solutions

The following data is based on the product molecular weight 584.73. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.71 mL 8.55 mL 17.1 mL
5 mM 0.34 mL 1.71 mL 3.42 mL
10 mM 0.17 mL 0.86 mL 1.71 mL
50 mM 0.03 mL 0.17 mL 0.34 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Parmee et al (1998) Discovery of L-755,507: a subnanomolar human β3 adrenergic receptor agonist. Bioorg.Med.Chem.Lett. 8 1107 PMID: 9871717

Fisher et al (1998) A selective human β3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J.Clin.Invest. 101 2387 PMID: 9616210

Yu et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 142 PMID: 25658371


If you know of a relevant reference for L-755,507, please let us know.

View Related Products by Product Action

View all Adrenergic β3 Receptor Agonists

Keywords: L-755,507, L-755,507 supplier, potent, selective, β3, beta3, partial, agonists, adrenergic, receptors, adrenoceptors, L755507, CRISPR, Cas9, HDR, NHEJ, homology, directed, repair, nonhomologous, end, joining, Adrenergic, Beta-3, Receptors, Reagents, 2197, Tocris Bioscience

4 Citations for L-755,507

Citations are publications that use Tocris products. Selected citations for L-755,507 include:

Afeli et al (2012) Do β3-adrenergic receptors play a role in guinea pig detrusor smooth muscle excitability and contractility?. Am J Physiol Renal Physiol 302 F251 PMID: 21993887

Coan et al (2009) Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem 52 2067 PMID: 19281222

Pinder et al (2015) Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res 43 9379 PMID: 26429972

Coan and Shoichet (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130 9606 PMID: 18588298


Do you know of a great paper that uses L-755,507 from Tocris? Please let us know.

Reviews for L-755,507

There are currently no reviews for this product. Be the first to review L-755,507 and earn rewards!

Have you used L-755,507?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.